Wellcome Sanger Institute: against COVID-19 Hub

1. Wellcome Sanger Institute participates in the 'COVID-19 Genomics UK (COG-UK) Consortium'

'COVID-19 Genomics UK (COG-UK) Consortium' is a collaboration between the NHS, Public Health England and other UK public health agencies, the Wellcome Sanger Institute, University of Cambridge and other academic institutions.

Project: COVID-19 Genomics UK (COG-UK) Consortium

Research Group: Cardiovascular Epidemiology Unit

Project Description: The COVID-19 Genomics UK (COG-UK) Consortium aims to increase the current capacity for SARS-CoV-2 genetic sequencing in the UK. This sequencing data will be used to understand the epidemiology and spread of the virus, and to monitor and evaluate interventions for COVID-19. SARS-CoV-2 genomic data will be integrated with NHS electronic health records and other existing genomic data to generate insights into susceptibility to COVID-19. From within the DPHPC, Professor John Danesh is a member of the COG-UK Steering Group, Dr Ewan Harrison will serve as the Scientific Project Manager and Dr Michael Chapman will lead the health informatics component.

2.
Wellcome Trust Sanger Institute is member of HDRUK Cambridge in collaboration with Department of Public Health and Primary Care and University of Cambridge. The institute participates in the project:

Project: HDRUK Cambridge COVID-19 Risk Factors Consortium

Research Group: Cardiovascular Epidemiology Unit

Project Description: The HDRUK Cambridge COVID-19 Risk Factors Consortium aims to understand risk factors for COVID-19, clinical trajectory and associated health outcomes through linkage of population and patient cohort bioresources led from Cambridge (with over 230,000 participants) with SARS-CoV-2 test results provided by Public Health England and other electronic health records. Once this data has been linked, researchers will be able to use this data to identify risk factors that influence susceptibility to SARS-CoV-2 infection and the likelihood of adverse consequences of infection.

--------------------------------------
Wellcome Sanger Institute is partner of the project 'COVID-19 Genomics UK (COG-UK) Consortium'
'COVID-19 Genomics UK (COG-UK) Consortium' is a collaboration between the NHS, Public Health England and other UK public health agencies, the Wellcome Sanger Institute, University of Cambridge and other academic institutions.

Project: COVID-19 Genomics UK (COG-UK) Consortium

Research Group: Cardiovascular Epidemiology Unit

Project Description: The COVID-19 Genomics UK (COG-UK) Consortium aims to increase the current capacity for SARS-CoV-2 genetic sequencing in the UK. This sequencing data will be used to understand the epidemiology and spread of the virus, and to monitor and evaluate interventions for COVID-19. SARS-CoV-2 genomic data will be integrated with NHS electronic health records and other existing genomic data to generate insights into susceptibility to COVID-19. From within the DPHPC, Professor John Danesh is a member of the COG-UK Steering Group, Dr Ewan Harrison will serve as the Scientific Project Manager and Dr Michael Chapman will lead the health informatics component.

Contributors:
The Wellcome Sanger Institute has a large team working to support the COG-UK network led by Dr Cordelia Langford, Ian Johnston, Dr Alex Alderton, Dr Matt Berriman, Dr Mara Lawniczak, Professor David Aanensen, John Sillitoe and Professor Dominic Kwiatkowski. Dr Ewan Harrison serves as Project Manager responsible for overall coordination of the COG-UK network.

The full of contributors can be seen here: https://www.sanger.ac.uk/covid-team

https://www.cogconsortium.uk/about/


Connections from

Headquarters: United Kingdom
Funding Status: N/A
Employee Number: N/A
Investment Stage: N/A
Number Of Exists: N/A
Technology: COVID Labs/Universities
Investor Type: N/A
Founded Date: N/A
Industry: COVID R&D